Related Experiment Video
Updated: Oct 31, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
Linda Waldherr1, Maria Seitanidou2, Marie Jakešová2
1Gottfried Schatz Research Center - Biophysics Medical University of Graz Graz 8010 Austria.
Abstract:
Successful treatment of glioblastoma multiforme (GBM), the most lethal tumor of the brain, is presently hampered by (i) the limits of safe surgical resection and (ii) "shielding" of residual tumor cells from promising chemotherapeutic drugs such as Gemcitabine (Gem) by the blood brain barrier (BBB). Here, the vastly greater GBM cell-killing potency of Gem compared to the gold standard temozolomide is confirmed, moreover, it shows neuronal cells to be at least 104-fold less sensitive to Gem than GBM cells. The study also demonstrates the potential of an electronically-driven organic ion pump ("GemIP") to achieve controlled, targeted Gem delivery to GBM cells. Thus, GemIP-mediated Gem delivery is confirmed to be temporally and electrically controllable with pmol min-1 precision and electric addressing is linked to the efficient killing of GBM cell monolayers. Most strikingly, GemIP-mediated GEM delivery leads to the overt disintegration of targeted GBM tumor spheroids. Electrically-driven chemotherapy, here exemplified, has the potential to radically improve the efficacy of GBM adjuvant chemotherapy by enabling exquisitely-targeted and controllable delivery of drugs irrespective of whether these can cross the BBB.
Insights
This study introduces Gemcitabine (Gem) as a potent glioblastoma drug, demonstrating an innovative ion pump for precise delivery. This technology overcomes the blood-brain barrier, enhancing chemotherapy efficacy for brain tumors.
Area of Science:
- Neuro-oncology
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Glioblastoma multiforme (GBM) is a lethal brain tumor with limited treatment options.
- Current therapies face challenges from surgical limitations and the blood-brain barrier (BBB) hindering drug penetration.
- Gemcitabine (Gem) shows higher potency against GBM cells than temozolomide, with lower toxicity to neuronal cells.
Purpose of the Study:
- To confirm the superior efficacy of Gemcitabine (Gem) over temozolomide for glioblastoma treatment.
- To demonstrate the potential of an electronically-driven organic ion pump (GemIP) for targeted Gem delivery.
- To evaluate the controlled, precise, and effective delivery of Gem via GemIP for GBM therapy.
Main Methods:
- Comparative drug-killing assays of Gemcitabine (Gem) against glioblastoma (GBM) and neuronal cells.
- Development and testing of an electronically-driven organic ion pump (GemIP) for drug delivery.
- Assessment of GemIP's temporal and electrical controllability in delivering Gem to GBM cell monolayers and spheroids.
Main Results:
- Gemcitabine (Gem) demonstrated significantly greater GBM cell-killing potency than temozolomide.
- Neuronal cells exhibited at least 10^4-fold less sensitivity to Gem compared to GBM cells.
- GemIP enabled precise, temporally and electrically controllable Gem delivery, leading to efficient killing of GBM monolayers and disintegration of tumor spheroids.
Conclusions:
- Gemcitabine (Gem) is a highly potent chemotherapeutic agent for glioblastoma (GBM).
- The electronically-driven ion pump (GemIP) offers a novel method for targeted and controlled drug delivery, overcoming BBB limitations.
- Electrically-driven chemotherapy holds significant potential to improve glioblastoma adjuvant treatment efficacy.
